Clinical Trials

Accrual Status
Limit to SWOG Trials

1049 Results

    View
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1900N

    A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
    Status Notes
    The above-referenced study will be open to participant accrual, effective 12:00 p.m. Pacific Time on August 3, 2026.
    Research Committee(s)
    LungMAP
    Activated
    08-03-2026
    ClinicalTrials.gov Registry Number
    07393555
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2504

    A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
    Status Notes
    Study is active as of 06/01/2026.
    Research Committee(s)
    Leukemia
    Lymphoma
    Activated
    06-01-2026
    ClinicalTrials.gov Registry Number
    07220187
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2424CD

    A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer
    Status Notes
    Activation 06/01/2026
    Research Committee(s)
    Cancer Care Delivery
    Activated
    06-01-2026
    ClinicalTrials.gov Registry Number
    07278739
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2419

    Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
    Status Notes
    Active as of 4/22/2026.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    04-22-2026
    ClinicalTrials.gov Registry Number
    NCT07383441
    Open
    Phase
    Accrual
    9%
    SWOG Clinical Trial Number
    SN2426

    A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Sarcoma
    Activated
    01-28-2026
    ClinicalTrials.gov Registry Number
    07042295
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2433

    Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-26-2025
    ClinicalTrials.gov Registry Number
    NCT06998940